Evaluation of the QMAC‐dRAST System Version 2.5 for Rapid Antimicrobial Susceptibility Testing of Gram‐Negative Bacteria From Positive Blood Culture Broth and Subcultured Colony Isolates
ABSTRACT Background Rapid antimicrobial susceptibility testing (AST) for bloodstream infections (BSIs) facilitates the optimization of antimicrobial therapy, preventing antimicrobial resistance and improving patient outcomes. QMAC‐dRAST (QuantaMatrix Inc., Korea) is a rapid AST platform based on mic...
Saved in:
Published in | Journal of clinical laboratory analysis Vol. 38; no. 9; pp. e25043 - n/a |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.05.2024
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | ABSTRACT
Background
Rapid antimicrobial susceptibility testing (AST) for bloodstream infections (BSIs) facilitates the optimization of antimicrobial therapy, preventing antimicrobial resistance and improving patient outcomes. QMAC‐dRAST (QuantaMatrix Inc., Korea) is a rapid AST platform based on microfluidic chip technology that performs AST directly using positive blood culture broth (PBCB). This study evaluated the performance of QMAC‐dRAST for Gram‐negative bacteria using PBCB and subcultured colony isolates, comparing it with that of VITEK 2 (bioMérieux, France) using broth microdilution (BMD) as the reference method.
Methods
We included 141 Gram‐negative blood culture isolates from patients with BSI and 12 carbapenemase‐producing clinical isolates of Enterobacterales spiked into blood culture bottles. QMAC‐dRAST performance was evaluated using PBCB and colony isolates, whereas VITEK 2 and BMD were tested only on colony isolates.
Results
For PBCB, QMAC‐dRAST achieved 92.1% categorical agreement (CA), 95.3% essential agreement (EA), with 1.8% very major errors (VMEs), 3.5% major errors (MEs), and 5.2% minor errors (mEs). With colony isolates, it exhibited 92.5% CA and 95.1% EA, with 2.0% VMEs, 3.2% MEs, and 4.8% mEs. VITEK 2 showed 94.1% CA and 96.0% EA, with 4.3% VMEs, 0.4% MEs, and 4.3% mEs. QMAC‐dRAST yielded elevated error rates for specific antimicrobial agents, with high VMEs for carbapenems and aminoglycosides. The median time to result for QMAC‐dRAST was 5.9 h for PBCB samples and 6.1 h for subcultured colony isolates.
Conclusions
The QMAC‐dRAST system demonstrated considerable strengths and comparable performance to the VITEK 2 system; however, challenges were discerned with specific antimicrobial agents, underlining a necessity for improvement.
The flowchart depicting the performance evaluation of QMAC‐dRAST version 2.5 in our study. BMD, broth microdilution; CA, categorical agreement; EA, essential agreement; ME, major error; mE, minor error; PBCB, positive blood culture broth; VME, very major error. |
---|---|
Bibliography: | This study was supported by QuantaMatrix Inc. (Seoul, Republic of Korea). The sponsor was not involved in the study design, data interpretation, or preparation of the manuscript. This study was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS‐2024‐00332244). Tae Yeul Kim and Minhee Kang contributed equally to this work. Funding ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Funding: This study was supported by QuantaMatrix Inc. (Seoul, Republic of Korea). The sponsor was not involved in the study design, data interpretation, or preparation of the manuscript. This study was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS‐2024‐00332244). |
ISSN: | 0887-8013 1098-2825 1098-2825 |
DOI: | 10.1002/jcla.25043 |